PAHC · XBRL financial data

Phibro Animal Health financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PAHC's year ends in late June)

In millions of dollars	FY 2021Jun 30, 2021	FY 2022†Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Revenue	833	—	—	—	—	—
Revenue from contracts with customers	833	942	978	1,018	1,296	1,518
Cost of goods and services sold	562	657	680	705	896	1,006
Gross profit	271	285	298	313	400	513
Research and development	18	21	24	29	24	25
Selling, general and administrative	197	206	226	260	289	318
Operating income (loss)	75	79	72	53	110	194
Interest expense	14	13	19	23	37	46
Income tax expense (benefit)	12	23	21	9	20	38
Net income (loss)	54	49	33	2	48	100
Earnings per share, basic USD per share	1.34	1.21	0.81	0.06	1.19	2.46
Earnings per share, diluted USD per share	1.34	1.21	0.81	0.06	1.19	2.43
Weighted average shares, basic millions of shares	0	41	41	41	41	41
Weighted average shares, diluted millions of shares	0	41	41	41	41	41

† Share count changed about 1000x in the period ending 2022-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (PAHC's year ends in late June)

In millions of dollars	FY 2021Jun 30, 2021	FY 2022†Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Cash and cash equivalents	50	74	41	71	68	61
Short-term investments	43	17	40	44	9	21
Accounts receivable	147	167	163	169	228	239
Inventory	216	259	278	266	444	535
Total current assets	499	566	586	601	811	936
Property and equipment, net	155	165	196	203	355	369
Right-of-use asset	33	38	36	38	41	52
Goodwill	53	53	53	55	60	60
Total assets	841	932	971	982	1,361	1,501
Accounts payable	68	96	74	86	138	127
Accrued liabilities	86	—	—	—	—	—
Current portion of long-term debt	—	15	22	30	16	25
Total current liabilities	164	191	176	204	293	316
Long-term debt	—	273	312	282	615	592
Lease liability, non-current	28	32	29	30	34	45
Total liabilities	603	669	689	726	1,075	1,116
Retained earnings	218	248	261	244	273	353
Total stockholders' equity	239	262	283	257	286	385
Total liabilities and equity	841	932	971	982	1,361	1,501

† Share count changed about 1000x in the period ending 2022-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (PAHC's year ends in late June)

In millions of dollars	FY 2021Jun 30, 2021	FY 2022†Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Net income (loss)	54	49	33	2	48	100
Stock-based compensation	1	—	—	0	1	2
Depreciation and amortization	32	33	34	36	46	52
Net cash from operating activities	48	32	13	88	80	69
Net cash from investing activities	(19)	(23)	(74)	(48)	(289)	(71)
Dividends paid	19	19	19	19	19	19
Net cash from financing activities	(17)	16	27	(7)	207	(7)
Net change in cash	14	24	(33)	29	(3)	(7)

† Share count changed about 1000x in the period ending 2022-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Phibro Animal Health	76	387	26	not reported	—	Q1 FY27 10-QSep 30, 2026
uniQure	98	5.2	(48)*	70.1M	2.6 quarters	Q3 FY26 10-QSep 30, 2026
Pacira BioSciences	206	192	57*	39.9M	—	Q2 FY26 10-QJun 30, 2026
Cogent Biosciences	181	not reported	(77)*	173.5M	10.3 quarters	Q2 FY26 10-QJun 30, 2026
Syndax Pharmaceuticals	136	83	(27)*	not reported	11.9 quarters	Q3 FY26 10-QSep 30, 2026
Immunome	218	0	(62)*	113.6M	8.4 quarters	Q2 FY26 10-QJun 30, 2026
Nurix Therapeutics	720	673	616*	109.2M	—	Q3 FY26 10-QAug 31, 2026
Niagen Bioscience	70	27	not reported	79.2M	—	Q3 FY26 10-QSep 30, 2026
Anavex Life Sciences	118	not reported	(9.1)*	92.7M	13.0 quarters	Q3 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.